Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma
Pediatric Investigation · 08.07.2026
DOI: 10.1002/ped4.70070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Investigation, online erschienen am 08.07.2026. Verfasst von Chenguang Jia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation Hematology Center Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatr…. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Importance The prognosis of pediatric refractory/relapsed non‐Hodgkin lymphoma (R/R NHL) remains poor, with limited evidence guiding optimal treatment. Haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) is a promising strategy for this high‐risk population. However, the optimal conditioning regimen and long‐term outcomes of haplo‐HSCT have not been fully elucidated.
Objective
To evaluate the long‐term efficacy and safety of antithymocyte globulin (ATG)‐based myeloablative haplo‐HSCT in pediatric patients with R/R NHL.
Methods
Pediatric patients with R/R NHL who underwent ATG‐based myeloablative haplo‐HSCT at Beijing Children's Hospital between March 2015 and December 2021 were retrospectively enrolled. Overall survival (OS) and progression‐free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log‐rank test.
Results
A total of 29 pediatric R/R NHL patients were enrolled, including 21 with lymphoblastic lymphoma and 8 with mature T‐cell and natural killer–cell lymphoma. The 5‐year OS, PFS, cumulative incidence of relapse, and non‐relapse mortality were 79.3%, 72.4%, 10.0%, and 17.0%, respectively. At a median follow‐up of 5.5 years, the cumulative incidences of Grade III–IV acute graft‐versus‐host disease (GVHD) and chronic GVHD were 13.8% (4/29) and 44.8% (13/29; predominantly mild), respectively. Thrombotic microangiopathy (TMA) developed in 12 patients and was associated with significantly inferior prognosis ( P = 0.001).
Interpretation
ATG‐based myeloablative haplo‐HSCT is a safe and effective treatment for pediatric R/R NHL, offering a viable alternative for patients lacking matched donors or requiring urgent intervention. Early detection and timely treatment of TMA may reduce mortality and improve survival outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation Hematology Center Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in…
- Department of Stem Cell Transplantation Baoding Children's Hospital Beijing Children's Hospital Capital Medical University National Center for Children's Health Baoding Hebei China.
ORCID-Profile: Chenguang Jia, Jie Zheng, Yanhui Luo, Yanlong Duan
Zitieren
APA
Jia, C., Zheng, J., Yuan, M., He, H., Fan, Y., Wang, B., Zhu, G., Yang, J., Luo, Y., Cai, L., Zhang, P., Duan, Y., & Qin, M. (2026). Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma. Pediatric Investigation. https://doi.org/10.1002/ped4.70070
Vancouver
Jia C, Zheng J, Yuan M, He H, Fan Y, Wang B, et al. Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma. Pediatric Investigation. 2026. doi:10.1002/ped4.70070
BibTeX
@article{Jia2026,
author = {Jia, Chenguang and Zheng, Jie and Yuan, Meng and He, Hongbo and Fan, Yibo and Wang, Bin and Zhu, Guanghua and Yang, Jun and Luo, Yanhui and Cai, Lixiao and Zhang, Pan and Duan, Yanlong and Qin, Maoquan},
title = {Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma},
journal = {Pediatric Investigation},
year = {2026},
doi = {10.1002/ped4.70070}
}
EUVIMED